AAV Potency Assay Using HPLC Cleavage-Product Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved methods to assess the efficacy of adeno-associated virus (AAV) vectors encoding enzymes, such as MTM1, that are sensitive and adaptable to high-throughput screening, particularly for treating diseases like X-linked myotubular myopathy, as existing methods lack sensitivity and efficiency.
Innovation Solution
The method involves contacting AAV vectors with AAV-permissive cells expressing a cleavable substrate, assessing the quantity or concentration of the cleavage product using high-performance liquid chromatography (HPLC) in the cell or extracellular media, to determine the efficacy of the vector for treating diseases associated with enzyme deficiencies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing methods are used to assess AAV vector efficacy, then the assessment can be performed, but the sensitivity and efficiency are insufficient for high-throughput screening
Solution Approach 1:
The patent changes the measurement parameter from qualitative/semi-quantitative methods to quantitative HPLC-based measurement of cleavage products. This allows precise determination of enzyme activity by measuring the concentration of cleaved substrate products, thereby improving both sensitivity and enabling high-throughput screening capability
Solution Approach 2:
The patent replaces traditional mechanical/chemical assay methods with chromatographic separation and detection (HPLC). This substitution provides more sensitive and quantitative measurement of enzyme activity, allowing efficient high-throughput assessment of AAV vector efficacy
2Reliability
If AAV vectors are used to treat loss-of-function diseases, then therapeutic effect can be achieved, but sensitive and adaptable assessment methods are needed
Solution Approach 1:
The patent segments the assessment process into distinct steps: (1) transduction of AAV vectors into cells, (2) expression of enzyme from AAV, (3) enzymatic cleavage of substrate, and (4) quantification of cleavage products by HPLC. This segmentation allows reliable assessment of therapeutic efficacy while making the methodology adaptable and systematic
3Productivity
If high-throughput screening is implemented, then productivity increases, but measurement sensitivity must be maintained
Solution Approach 1:
The patent employs a cell-based assay where the AAV-permissive cells themselves perform the transduction and enzyme expression functions. This self-service approach allows high-throughput screening while maintaining sensitivity, as each cell automatically processes the AAV vector and produces measurable cleavage products without requiring complex external intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for sensitive and quantitative assessment of AAV vector efficacy, enabling effective treatment of loss-of-function diseases by identifying vectors that increase the concentration of cleavage products or decrease substrate levels, thus facilitating high-throughput screening and therapeutic administration.
Implementation Method 1
assessing a quantity or concentration of a product resulting from cleavage of the substrate by the enzyme
Implementation Method 2
assessing, by way of chromatography, a quantity or concentration of the substrate or of a product resulting from cleavage of the substrate by the enzyme
Data Source
AI summary
Some embodiments relate to methods and kits for detecting and monitoring the potency of an enzyme encoded by an adeno-associated virus. Exemplary enzymes that may be used in conjunction with the compositions and methods of the disclosure are Myotubularin 1 (MTM1) and myotubularin-related proteins, such as myotubularin-related protein 1 (MTMR1), MTMR2, MTMR3, MTMR4, MTMR5, MTMR6, MTMR7, MTMR8, MTMR9, MTMR10, MTMR11, MTMR12, MTMR12, MTMR13, and MTMR14, among others.